Sphingosine kinase 1 promotes tumour cell migration and invasion via the S1P/EDG1 axis in hepatocellular carcinoma

Liver International

Volumn 32, Issue 2, 2012, Pages 331-338

  Bao, Meiyan ^a   Chen, Zhiao ^a   Xu, Yongfen ^a   Zhao, Yingjun ^a   Zha, Ruopeng ^a   Huang, Shenglin ^a   Liu, Li ^a   Chen, Taoyang ^b   Li, Jinjun ^a   Tu, Hong ^a   He, Xianghuo ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b Qi Dong Liver Cancer Institute   (China)

Author keywords

EDG1; Hepatocellular carcinoma; Invasion; Migration; S1P; Sphingosine kinase 1 (SphK1)

Indexed keywords

G PROTEIN COUPLED RECEPTOR; MESSENGER RNA; PROTEIN CDC42; RAC1 PROTEIN; SMALL INTERFERING RNA; SPHINGOLIPID G PROTEIN COUPLED RECEPTOR 5; SPHINGOSINE 1 PHOSPHATE; SPHINGOSINE KINASE 1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER INVASION; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER METASTASIS; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN SECRETION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING;

CARCINOMA, HEPATOCELLULAR; CELL MOVEMENT; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HUMANS; LIVER NEOPLASMS; NEOPLASM INVASIVENESS; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); RECEPTORS, LYSOSPHINGOLIPID; RNA, SMALL INTERFERING; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 84855544340     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2011.02666.x     Document Type: Article

References (33)

1. Sugiura M, Kono K, Liu H, et al. Ceramide kinase, a novel lipid kinase. Molecular cloning and functional characterization. J Biol Chem 2002; 277: 23294-300.
2. Ogretmen B, Hannun YA. Biologically active sphingolipids in cancer pathogenesis and treatment. Nat Rev Cancer 2004; 4: 604-16.
3. French KJ, Schrecengost RS, Lee BD, et al. Discovery and evaluation of inhibitors of human sphingosine kinase. Cancer Res 2003; 63: 5962-9.
4. Sarkar S, Maceyka M, Hait NC, et al. Sphingosine kinase 1 is required for migration, proliferation and survival of MCF-7 human breast cancer cells. FEBS Lett 2005; 579: 5313-7.
5. Kohno M, Momoi M, Oo ML, et al. Intracellular role for sphingosine kinase 1 in intestinal adenoma cell proliferation. Mol Cell Biol 2006; 26: 7211-23.
6. Pyne NJ, Pyne S. Sphingosine 1-phosphate and cancer. Nat Rev Cancer 2010; 10: 489-503.
7. Li J, Guan HY, Gong LY, et al. Clinical significance of sphingosine kinase-1 expression in human astrocytomas progression and overall patient survival. Clin Cancer Res 2008; 14: 6996-7003.
8. Kawamori T, Kaneshiro T, Okumura M, et al. Role for sphingosine kinase 1 in colon carcinogenesis. FASEB J 2009; 23: 405-14.
9. Pchejetski D, Doumerc N, Golzio M, et al. Chemosensitizing effects of sphingosine kinase-1 inhibition in prostate cancer cell and animal models. Mol Cancer Ther 2008; 7: 1836-45.
10. Akao Y, Banno Y, Nakagawa Y, et al. High expression of sphingosine kinase 1 and S1P receptors in chemotherapy-resistant prostate cancer PC3 cells and their camptothecin-induced up-regulation. Biochem Biophys Res Commun 2006; 342: 1284-90.
11. Schwartz GK, Ward D, Saltz L, et al. A pilot clinical/pharmacological study of the protein kinase C-specific inhibitor safingol alone and in combination with doxorubicin. Clin Cancer Res 1997; 3: 537-43.
12. Gamble JR, Xia P, Hahn CN, et al. Phenoxodiol, an experimental anticancer drug, shows potent antiangiogenic properties in addition to its antitumour effects. Int J Cancer 2006; 118: 2412-20.
13. Marshall EI. A Phase II Trial of Phenoxodiol in Patients With Castrate and Non-Castrate Prostate Cancer. Available at Accessed: 6 April 2010.
14. Marshall EI. A Phase III Study of Weekly Carboplatin With and Without Phenoxodiol in Patients With Platinum-Resistant, Recurrent Epithelial Ovarian Cancer. Available at, Accessed: 3 December 2010.
15. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007; 132: 2557-76.
16. Tang ZY. Hepatocellular carcinoma - cause, treatment and metastasis. World J Gastroenterol 2001; 7: 445-54.
17. Hoti E, Adam R. Liver transplantation for primary and metastatic liver cancers. Transpl Int 2008; 21: 1107-17.
18. Wan D, Gong Y, Qin W, et al. Large-scale cDNA transfection screening for genes related to cancer development and progression. Proc Natl Acad Sci U S A 2004; 101: 15724-9.
19. Kluk MJ, Hla T. Signaling of sphingosine-1-phosphate via the S1P/EDG-family of G-protein-coupled receptors. Biochim Biophys Acta 2002; 1582: 72-80.
20. Alvarez SE, Milstien S, Spiegel S. Autocrine and paracrine roles of sphingosine-1-phosphate. Trends Endocrinol Metab 2007; 18: 300-7.
21. Steeg PS. Tumor metastasis: mechanistic insights and clinical challenges. Nat Med 2006; 12: 895-904.
22. Ye SL, Takayama T, Geschwind J, Marrero JA, Bronowicki JP. Current approaches to the treatment of early hepatocellular carcinoma. Oncologist 2010; 15(Suppl. 4): 34-41.
23. Lencioni R, Chen XP, Dagher L, Venook AP. Treatment of intermediate/advanced hepatocellular carcinoma in the clinic: how can outcomes be improved? Oncologist 2010; 15(Suppl. 4): 42-52.
24. Lee OH, Kim YM, Lee YM, et al. Sphingosine 1-phosphate induces angiogenesis: its angiogenic action and signaling mechanism in human umbilical vein endothelial cells. Biochem Biophys Res Commun 1999; 264: 743-50.
25. Spiegel S, Milstien S. Sphingosine-1-phosphate: an enigmatic signalling lipid. Nat Rev Mol Cell Biol 2003; 4: 397-407.
26. von Otte S, Paletta JR, Becker S, et al. Follicular fluid high density lipoprotein-associated sphingosine 1-phosphate is a novel mediator of ovarian angiogenesis. J Biol Chem 2006; 281: 5398-405.
27. Sabbadini RA. Targeting sphingosine-1-phosphate for cancer therapy. Br J Cancer 2006; 95: 1131-5.
28. Lee MJ, Van Brocklyn JR, Thangada S, et al. Sphingosine-1-phosphate as a ligand for the G protein-coupled receptor EDG-1. Science 1998; 279: 1552-5.
29. Gardell SE, Dubin AE, Chun J. Emerging medicinal roles for lysophospholipid signaling. Trends Mol Med 2006; 12: 65-75.
30. Yamashita H, Kitayama J, Shida D, et al. Sphingosine 1-phosphate receptor expression profile in human gastric cancer cells: differential regulation on the migration and proliferation. J Surg Res 2006; 130: 80-87.
31. Arikawa K, Takuwa N, Yamaguchi H, et al. Ligand-dependent inhibition of B16 melanoma cell migration and invasion via endogenous S1P2 G protein-coupled receptor. Requirement of inhibition of cellular RAC activity. J Biol Chem 2003; 278: 32841-51.
32. Milstien S, Spiegel S. Targeting sphingosine-1-phosphate: a novel avenue for cancer therapeutics. Cancer Cell 2006; 9: 148-50.
33. Malchinkhuu E, Sato K, Maehama T, et al. S1P(2) receptors mediate inhibition of glioma cell migration through Rho signaling pathways independent of PTEN. Biochem Biophys Res Commun 2008; 366: 963-8.